Risk for developing new-onset constipation low among GLP-1 users with obesity

Although nearly a third of individuals with obesity who use GLP-1 receptor agonists experience constipation, the risk for developing constipation among new users appears “quite low,” according to researchers.“Constipation is one of the most commonly discussed gastrointestinal side effects of GLP-1 receptor agonists, and it is often cited as a reason patients stop therapy,”